Kieuhoa Vo, MD
Enriched profileAssociate Professor, Pediatrics · University of California, San Francisco
Kieuhoa Vo is Associate Professor, Pediatrics at University of California, San Francisco. OpenAlex indexes 57 publications with 1,355 citations (h-index 18); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 27 Oct 2026
Overview
Updated 28 Oct 2026
Kieuhoa Vo, MD, is Associate Professor, Pediatrics at University of California, San Francisco. The public record shows 57 publications with 1,355 citations (h-index 18), centered on Sarcoma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Glioma Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Sarcoma Diagnosis and Treatment
- 12 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 26.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
Sponsor: National Cancer Institute (NCI)
- A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Sponsor: St. Jude Children's Research Hospital
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
Updated 28 Oct 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma
University of California, San Francisco
FY2026$535,047R01CA285681 - Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma
University of California, San Francisco
FY2025$540,607R01CA285681 - Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma
University of California, San Francisco
FY2024$573,379R01CA285681
Congress activity
Updated 28 Oct 2026
13 congress contributions (2017–2026) across AACR, ASCO per OpenAlex. The most recent:
- Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.
ASCO Annual Meeting
ASCO2026Co-author - Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 28 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.
Clinical cancer research
Clinical Trial2026 - Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Journal of clinical oncology
Clinical Trial2025 - A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
Pediatric blood & cancer
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)Network
Updated 28 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Board certified: American Board of Pediatrics
Pediatric Hematology-Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfbenioffchildrens.org ↗
Editorial & leadership roles
journal and society appointments- Director
Early Phase Clinical Trials Program (Pediatric Oncology), UCSF
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →braintumorcenter.ucsf.edu ↗ - Director
MIBG Therapy Program, UCSF
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfbenioffchildrens.org ↗ - Site Principal Investigator
Children's Oncology Group Pediatric Early Phase Clinical Trials Network (PEP-CTN) and New Approaches to Neuroblastoma Therapy (NANT) consortium
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →braintumorcenter.ucsf.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →braintumorcenter.ucsf.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Adil Daud, MD
University of California, San Francisco
Emmanuelle Waubant, MD
University of California, San Francisco
Peter Ganz, MD
University of California, San Francisco
Joel Palefsky, MD
University of California, San Francisco
George Demetri, MD
Dana-Farber Cancer Institute; Professor of Medicine
Alberto Pappo, MD
St. Jude Children's Research Hospital
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
William Tap, MD
Memorial Sloan Kettering Cancer Center